Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Hodgkin Disease 7Multiple Myeloma 6Leukemia 6Neoplasm Metastasis 5Myelodysplastic Syndromes 5Lymphoma, Non-Hodgkin 5Lymphoma 5Leukemia, Myeloid, Chronic-Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Prostatic Neoplasms 4Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Graft vs Host Disease 4Blast Crisis 4Sarcoma 3Primary Myelofibrosis 3Pancreatic Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma, Large B-Cell, Diffuse 3Burkitt Lymphoma 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2

Interventions

temsirolimus 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Recurrent Uterine Sarcoma × Sirolimus × Clear all
NCT01061606 2016-11-09

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Terminated
8 enrolled 6 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡